Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus

Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in... ORIGINAL INVESTIGATION Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus Adriaan Kooy, MD, PhD; Jolien de Jager, MD; Philippe Lehert, PhD; Daniël Bets, MSc; Michiel G. Wulffele´, MD, PhD; Ab J. M. Donker, MD, PhD; Coen D. A. Stehouwer, MD, PhD Background: We investigated whether metformin hy- groups, and reduced insulin requirements (mean reduc- drochloride has sustained beneficial metabolic and (car- tion, 19.63 IU/d [95% CI, 24.91-14.36 IU/d]; P .001). dio) vascular effects in patients with type 2 diabetes melli- Metformin was not associated with an improvement in tus (DM2). the primary end point. It was, however, associated with an improvement in the secondary, macrovascular end Methods: We studied 390 patients treated with insulin point (hazard ratio, 0.61 (95% CI, 0.40-0.94; P = .02), in the outpatient clinics of 3 hospitals in a randomized, which was partly explained by the difference in weight. placebo-controlled trial with a follow-up period of 4.3 The number needed to treat to prevent 1 macrovascular years. Either metformin hydrochloride, 850 mg, or pla- end point was 16.1 (95% CI, 9.2-66.6). cebo (1-3 times daily) was added to insulin therapy. The primary end point was http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus

Download PDF
10 pages

Loading next page...
 
/lp/american-medical-association/long-term-effects-of-metformin-on-metabolism-and-microvascular-and-dLh671N0sg

References (48)

Publisher
American Medical Association
Copyright
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinternmed.2009.20
pmid
19307526
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL INVESTIGATION Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus Adriaan Kooy, MD, PhD; Jolien de Jager, MD; Philippe Lehert, PhD; Daniël Bets, MSc; Michiel G. Wulffele´, MD, PhD; Ab J. M. Donker, MD, PhD; Coen D. A. Stehouwer, MD, PhD Background: We investigated whether metformin hy- groups, and reduced insulin requirements (mean reduc- drochloride has sustained beneficial metabolic and (car- tion, 19.63 IU/d [95% CI, 24.91-14.36 IU/d]; P .001). dio) vascular effects in patients with type 2 diabetes melli- Metformin was not associated with an improvement in tus (DM2). the primary end point. It was, however, associated with an improvement in the secondary, macrovascular end Methods: We studied 390 patients treated with insulin point (hazard ratio, 0.61 (95% CI, 0.40-0.94; P = .02), in the outpatient clinics of 3 hospitals in a randomized, which was partly explained by the difference in weight. placebo-controlled trial with a follow-up period of 4.3 The number needed to treat to prevent 1 macrovascular years. Either metformin hydrochloride, 850 mg, or pla- end point was 16.1 (95% CI, 9.2-66.6). cebo (1-3 times daily) was added to insulin therapy. The primary end point was

Journal

JAMA Internal Medicine – American Medical Association

Published: Mar 23, 2009

There are no references for this article.